Skip to content
Open access

A 52‐Week Efficacy and Safety Study of Teneligliptin, as an Add‐On to Empagliflozin and Metformin in Patients With Type 2 Diabetes Mellitus: A Randomised, Double‐Blind, Placebo‐Controlled Phase 3 Trial (TERA305 Study)

Oct 2026 · Diabetes, obesity and metabolism · Vol 28, pp. 11955 - 11965 · 0 citations · 18 references
Medicine

Abstract

To evaluate the long‐term efficacy and safety of teneligliptin add‐on in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and empagliflozin.

Read PDF

Similar papers

Open access Sep 2026

Effectiveness and Safety of Fixed‐Dose Combination Metformin and Empagliflozin in Type 2 Diabetes: A Prospective, Multicenter, Real‐World Study From China

This study assessed the real‐world effectiveness and safety of a fixed‐dose combination (FDC) of metformin and empagliflozin in Chinese patients with type 2 diabetes mellitus (T2DM).

Wei-Jian Ke, Ying-Hong Kong, Song-Bo Fu et al. · 0 citations
Sep 2026

Effectiveness, Safety and Pharmacokinetics of BGM0504, a Dual GLP‐1/GIP Receptor Agonist, in Chinese Adults With Overweight or Obesity Without Diabetes: A Phase 2 Multicentre, Randomized, Double‐Blind, Placebo‐Controlled Trial

To evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and efficacy of the dual GLP‐1R/GIPR agonist BGM0504 in Chinese adults with overweight or obesity without diabetes.

L. Ji, Guo-Ping Yang, Yang-Qing Huang et al. · 0 citations
Open access Sep 2026

Oral Semaglutide in Routine Clinical Practice: 24‐Month Real‐World Effectiveness, Persistence and Safety in Adults With Type 2 Diabetes

Real‐world long‐term data on oral semaglutide are limited. We evaluated its 24‐month effectiveness, persistence, and safety in adults with type 2 diabetes (T2D).

M. P. A. Baldassarre, G. Di Dalmazi, Federica Carrieri et al. · 0 citations
Open access Oct 2026

Clinical trial: The Effect on Intragastric pH and Pharmacokinetics of the PCAB Linaprazan Glurate in Healthy Subjects After Repeat‐Dose Administration for up to 14 Days

Linaprazan glurate (LG), a potassium‐competitive acid blocker (PCAB), has shown up to 100% and 93% 4‐week healing rates in a Phase 2 study in patients with LA grade A/B and C/D erosive oesophagitis, respectively.

Kajsa Larsson, Kjell Andersson, Gunilla Huledal et al. · 0 citations
Open access Oct 2026

Efficacy and Safety of Crisugabalin for Inadequately Controlled Diabetic Peripheral Neuropathic Pain: A Randomized, Active‐Controlled, Phase 2 Trial

Crisugabalin (HSK16149), a selective γ‐aminobutyric acid (GABA) analog, has shown preliminary efficacy in controlling diabetic peripheral neuropathic pain (DPNP), but efficacy in patients with inadequate response to prior pregabalin treatment remains unknown.

Ya-Ming Li, Fang Zhang, Wei Liu et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.